Sera Prognostics Expands Medicaid Coverage and Commercial Partnerships — Sera Prognostics, Inc. (The Pregnancy Company)

Event summary

Launched fourth partnership program in August 2026, expanding PreTRM® Test-guided care through a state-based initiative with a national payer.
Illinois Medicaid now mandates coverage for PreTRM-Test, affecting approximately 50,000 annual Medicaid births.
Published PRIME study subgroup analysis showing PreTRM test-guided care reduced NICU admissions by 22% among first-time mothers.
Ended Q2 2026 with $80.3 million in cash, sufficient to fund operations through 2029.

The big picture

Sera Prognostics is making strides in expanding access to its PreTRM® Test, a critical tool for predicting preterm birth risk. The company's strategic focus on payer engagement, regulatory readiness, and clinical evidence generation aligns with broader industry trends toward precision medicine and value-based healthcare. With a strong cash position and growing commercial momentum, Sera Prognostics is positioning itself for significant adoption milestones in the coming years.

What we're watching

Commercial Adoption: Whether Sera Prognostics can sustain the month-to-month increase in testing volume following the PRIME study publication.
Regulatory Progress: The pace at which European regulatory approval advances, with CE marking submission expected by Q4 2026.
Market Expansion: How the fourth partnership program and Illinois Medicaid mandate will influence payer engagement across other states.